FernandesSL, CarvalhoRR, SantosLG, SáFM, RuivoC, MendesSL, MartinsH, et al. Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. Arq. Bras. Cardiol. 2020;114(1):120-9.
Fernandes,Sara Lopes; Carvalho,Rita Ribeiro; Santos,Luís Graça; Sá,Fernando Montenegro; Ruivo,Catarina; Mendes,Sofia Lázaro; Martins,Hélia; Morais,João Araujo. Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. Arq. Bras. Cardiol., v. 114, n. 1, p. 120-129, Jan. 2020.
Fernandes,S.L., Carvalho,R.R., Santos,L.G., Sá,F.M., Ruivo,C., Mendes,S.L., Martins,H., & Morais,J.A. (2020). Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. Arq. Bras. Cardiol.,114(1), 120-129.
Fernandes,Sara Lopes and Carvalho,Rita Ribeiro and Santos,Luís Graça and Sá,Fernando Montenegro and Ruivo,Catarina and Mendes,Sofia Lázaro and Martins,Hélia and Morais,João Araujo. Pathophysiology and Treatment of Heart Failure with Preserved Ejection Fraction: State of the Art and Prospects for the Future. Arq. Bras. Cardiol. [online]. 2020, vol. 114, n. 1, [cited 2025-09-06], pp.120-129. Available from: <https://abccardiol.org/en/article/pathophysiology-and-treatment-of-heart-failure-with-preserved-ejection-fraction-state-of-the-art-and-prospects-for-the-future/>. ISSN 0066-782X.
Figure 1
Dyslipidemia as a central element in atherosclerotic cardiovascular disease. ASCVD: atherosclerotic cardiovascular disease; LDL-C: low-density lipoprotein cholesterol. Limitations of statin-based therapy (non-exhaustive) include suboptimal LDL-C goal attainment, statin-associated adverse effects that may affect adherence, and potential drug interactions. Residual risk reflects the involvement of multiple underlying pathways.
